insights_auto
Why is OPHLY up 5.91%?
Dive Deeperchevron_right
OPHLY:OTCMKTS
Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
$4.92
arrow_upward
+5.91%(+0.28) 1D
Oct 15, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for OPHLY...
Open
$4.96
High
$4.96
Low
$4.90
Mkt. cap
1.20T
Avg. vol.
61.54K
Volume
68.37K
52-wk high
$5.75
52-wk low
$3.82
Beta
0.21
Shares outstanding
1.50B
No. of employees
4K
Open
$4.96
High
$4.96
Low
$4.90
Mkt. cap
1.20T
Avg. vol.
61.54K
Volume
68.37K
52-wk high
$5.75
52-wk low
$3.82
Beta
0.21
Shares outstanding
1.50B
No. of employees
4K
News stories
From web sources and news partners
FXStreet
·
26 minutes ago
Dow Jones futures lead market gains following comments from US financial leaders
Bloomberg
·
42 minutes ago
European Shares Outperform S&P 500 Amid Defensive Tilt From AI
TradingView
·
1 hour ago
Stock Market: Will S&P 500 Open Up or Down Today?
Yahoo Finance
·
9 hours ago
Grayscale Says Bitcoin’s Volatility Falls to 43%, Now Within S&P 500 Range
Profile
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
About Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
CEOGyo Sagara | Gyo Sagara
Employees4.21K
Founded1717
HeadquartersOsaka, Osaka, Japan
SectorPharmaceutical industry
Websiteono-pharma.com